{"pmid":32349935,"pmcid":"PMC7172651","title":"Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?","text":["Corticosteroids for Urological Cancer Care During Coronavirus Disease 2019. Treat or Not to Treat?","The current World Health Organization guidance is not to start corticosteroids, but there is no robust evidence of risk in patients with cancer and coronavirus disease 2019. A risk-benefit analysis should be performed for each patient on the use of steroids in cancer care.","Eur Urol","Waterhouse, Jasmin V","Hull, James H","Linch, Mark","32349935"],"abstract":["The current World Health Organization guidance is not to start corticosteroids, but there is no robust evidence of risk in patients with cancer and coronavirus disease 2019. A risk-benefit analysis should be performed for each patient on the use of steroids in cancer care."],"journal":"Eur Urol","authors":["Waterhouse, Jasmin V","Hull, James H","Linch, Mark"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32349935","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.eururo.2020.04.027","e_drugs":["Steroids"],"topics":["Prevention"],"weight":1,"_version_":1666138495722192896,"score":9.490897,"similar":[{"pmid":32256706,"pmcid":"PMC7105332","title":"COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?","text":["COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?","Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients.","Ecancermedicalscience","Russell, Beth","Moss, Charlotte","Rigg, Anne","Van Hemelrijck, Mieke","32256706"],"abstract":["Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients."],"journal":"Ecancermedicalscience","authors":["Russell, Beth","Moss, Charlotte","Rigg, Anne","Van Hemelrijck, Mieke"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32256706","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3332/ecancer.2020.1023","keywords":["covid-19","sars-cov-2","corticosteroids","non-steroidal anti-inflammatory drugs"],"topics":["Treatment"],"weight":1,"_version_":1666138493121724416,"score":99.74266},{"pmid":32377176,"pmcid":"PMC7201379","title":"Pancreatic Cancer During COVID-19 Pandemic: Treat or Not to Treat?","text":["Pancreatic Cancer During COVID-19 Pandemic: Treat or Not to Treat?","Pancreatic cancer is a very aggressive disease and survival remains dismal even with treatment. Currently, management of patients with pancreatic cancer has been complicated by the ongoing COVID-19 pandemic. Medical oncologists face the dilemma of whether to treat or to not treat these patients who are at high-risk of complications and even death from COVID-19. No current guidelines are available and our limited experience at this time makes it more difficult to manage these patients. Although we have general strategies available from experience in Italy, we need more treatment specific strategies to help mitigate risks of complications and toxicities from chemotherapy in order to protect our patients from COVID-19 as much as possible.","JOP","Patel, Rajvi","Saif, Wasif","32377176"],"abstract":["Pancreatic cancer is a very aggressive disease and survival remains dismal even with treatment. Currently, management of patients with pancreatic cancer has been complicated by the ongoing COVID-19 pandemic. Medical oncologists face the dilemma of whether to treat or to not treat these patients who are at high-risk of complications and even death from COVID-19. No current guidelines are available and our limited experience at this time makes it more difficult to manage these patients. Although we have general strategies available from experience in Italy, we need more treatment specific strategies to help mitigate risks of complications and toxicities from chemotherapy in order to protect our patients from COVID-19 as much as possible."],"journal":"JOP","authors":["Patel, Rajvi","Saif, Wasif"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32377176","source":"PubMed","week":"202019|May 04 - May 10","keywords":["adjuvant chemotherapy","covid-19, pandemics","lymphopenia","neutropenia","pancreatic cancer"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666262687572557825,"score":91.54118},{"pmid":32401670,"title":"Treatment of COVID-19 exacerbated asthma: should systemic corticosteroids be used?","text":["Treatment of COVID-19 exacerbated asthma: should systemic corticosteroids be used?","Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is a new rapidly spreading infectious disease. Current guidance from the World Health Organisation (WHO) highlights asthmatics as a high-risk group for severe illness from COVID-19. Viruses are common triggers of asthma exacerbations and the current SARS-CoV-2 pandemic raises several questions regarding the optimum management strategies. Here, we discuss the contentious issue of whether the mainstay therapies systemic corticosteroids should be used in the routine management of COVID-19-associated asthma exacerbations. Recent guidance from the WHO has advised against the use of corticosteroids if COVID-19 is suspected due to concerns that these agents may impair protective innate anti-viral immune responses. This may not be appropriate in the unique case of asthma exacerbation, a syndrome associated with augmented type 2 inflammation, a disease feature that is known to directly inhibit anti-viral immunity. Corticosteroids, through their suppressive effects on type 2 inflammation, are thus likely to restore impaired anti-viral immunity in asthma and, in contrast to non-asthmatic subjects, have beneficial clinical effects in the context of SARS-CoV-2 infection.","Am J Physiol Lung Cell Mol Physiol","Kumar, Kartik","Hinks, Timothy Sc","Singanayagam, Aran","32401670"],"abstract":["Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is a new rapidly spreading infectious disease. Current guidance from the World Health Organisation (WHO) highlights asthmatics as a high-risk group for severe illness from COVID-19. Viruses are common triggers of asthma exacerbations and the current SARS-CoV-2 pandemic raises several questions regarding the optimum management strategies. Here, we discuss the contentious issue of whether the mainstay therapies systemic corticosteroids should be used in the routine management of COVID-19-associated asthma exacerbations. Recent guidance from the WHO has advised against the use of corticosteroids if COVID-19 is suspected due to concerns that these agents may impair protective innate anti-viral immune responses. This may not be appropriate in the unique case of asthma exacerbation, a syndrome associated with augmented type 2 inflammation, a disease feature that is known to directly inhibit anti-viral immunity. Corticosteroids, through their suppressive effects on type 2 inflammation, are thus likely to restore impaired anti-viral immunity in asthma and, in contrast to non-asthmatic subjects, have beneficial clinical effects in the context of SARS-CoV-2 infection."],"journal":"Am J Physiol Lung Cell Mol Physiol","authors":["Kumar, Kartik","Hinks, Timothy Sc","Singanayagam, Aran"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401670","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1152/ajplung.00144.2020","keywords":["asthma","covid-19","corticosteroid","exacerbation"],"topics":["Treatment"],"weight":1,"_version_":1666865855080693760,"score":88.91433},{"pmid":32401686,"title":"Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic.","text":["Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic.","Cancer has become a prevalent disease, affecting millions of new patients globally each year. The COVID-19 pandemic is having far-reaching impacts around the world, causing substantial disruptions to health and health care systems that are likely to last for a prolonged period. Early data have suggested that having cancer is a significant risk factor for mortality from severe COVID-19. A diverse group of medical oncologists met to formulate detailed practical advice on systemic anticancer treatments during this crisis. In the context of broad principles, issues including risks of treatment, principles of prioritizing resources, treatment of elderly patients, and psychosocial impact are discussed. Detailed treatment advice and options are given at a tumor stream level. We must maintain care for patients with cancer as best we can and recognize that COVID-19 poses a significant competing risk for death that changes conventional treatment paradigms.","JCO Oncol Pract","Segelov, Eva","Underhill, Craig","Prenen, Hans","Karapetis, Christos","Jackson, Christopher","Nott, Louise","Clay, Tim","Pavlakis, Nick","Sabesan, Sabe","Heywood, Ellen","Steer, Christopher","Lethborg, Carrie","Gan, Hui K","Yip, Desmond","Karanth, Narayan","Karikios, Deme","MacIntyre, C Raina","32401686"],"abstract":["Cancer has become a prevalent disease, affecting millions of new patients globally each year. The COVID-19 pandemic is having far-reaching impacts around the world, causing substantial disruptions to health and health care systems that are likely to last for a prolonged period. Early data have suggested that having cancer is a significant risk factor for mortality from severe COVID-19. A diverse group of medical oncologists met to formulate detailed practical advice on systemic anticancer treatments during this crisis. In the context of broad principles, issues including risks of treatment, principles of prioritizing resources, treatment of elderly patients, and psychosocial impact are discussed. Detailed treatment advice and options are given at a tumor stream level. We must maintain care for patients with cancer as best we can and recognize that COVID-19 poses a significant competing risk for death that changes conventional treatment paradigms."],"journal":"JCO Oncol Pract","authors":["Segelov, Eva","Underhill, Craig","Prenen, Hans","Karapetis, Christos","Jackson, Christopher","Nott, Louise","Clay, Tim","Pavlakis, Nick","Sabesan, Sabe","Heywood, Ellen","Steer, Christopher","Lethborg, Carrie","Gan, Hui K","Yip, Desmond","Karanth, Narayan","Karikios, Deme","MacIntyre, C Raina"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401686","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1200/OP.20.00229","topics":["Treatment","Prevention"],"weight":1,"_version_":1666714494910332928,"score":87.59941},{"pmid":32392559,"title":"Treating Leukemia in the Time of COVID-19.","text":["Treating Leukemia in the Time of COVID-19.","The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to the management of patients with leukemia. The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted therapies (venetoclax, FLT3 inhibitors, IDH1/2 inhibitors, Bruton's tyrosine kinase inhibitors), introduce additional layers of complexity during COVID-19 high-risk periods. The knowledge about COVID-19 is accumulating rapidly. An important distinction is the prevalence of \"exposure\" versus \"clinical infectivity,\" which determine the risk versus benefit of modifying potentially highly curative therapies in leukemia. At present, the rate of clinical infection is <1-2% worldwide. With a mortality rate of 1-5% in CO-VID-19 patients in the general population and potentially of >30% in patients with cancer, careful consideration should be given to the risk of COVID-19 in leukemia. Instead of reducing patient access to specialized cancer centers and modifying therapies to ones with unproven curative benefit, there is more rationale for less intensive, yet effective therapies that may require fewer clinic visits or hospitalizations. Here, we offer recommendations on the optimization of leukemia management during high-risk COVID-19 periods.","Acta Haematol","Paul, Shilpa","Rausch, Caitlin R","Jain, Nitin","Kadia, Tapan","Ravandi, Farhad","DiNardo, Courtney D","Welch, Mary Alma","Dabaja, Bouthaina S","Daver, Naval","Garcia-Manero, Guillermo","Wierda, William","Pemmaraju, Naveen","Montalban Bravo, Guillermo","Thompson, Philip","Verstovsek, Srdan","Konopleva, Marina","Kantarjian, Hagop","Jabbour, Elias","32392559"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to the management of patients with leukemia. The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted therapies (venetoclax, FLT3 inhibitors, IDH1/2 inhibitors, Bruton's tyrosine kinase inhibitors), introduce additional layers of complexity during COVID-19 high-risk periods. The knowledge about COVID-19 is accumulating rapidly. An important distinction is the prevalence of \"exposure\" versus \"clinical infectivity,\" which determine the risk versus benefit of modifying potentially highly curative therapies in leukemia. At present, the rate of clinical infection is <1-2% worldwide. With a mortality rate of 1-5% in CO-VID-19 patients in the general population and potentially of >30% in patients with cancer, careful consideration should be given to the risk of COVID-19 in leukemia. Instead of reducing patient access to specialized cancer centers and modifying therapies to ones with unproven curative benefit, there is more rationale for less intensive, yet effective therapies that may require fewer clinic visits or hospitalizations. Here, we offer recommendations on the optimization of leukemia management during high-risk COVID-19 periods."],"journal":"Acta Haematol","authors":["Paul, Shilpa","Rausch, Caitlin R","Jain, Nitin","Kadia, Tapan","Ravandi, Farhad","DiNardo, Courtney D","Welch, Mary Alma","Dabaja, Bouthaina S","Daver, Naval","Garcia-Manero, Guillermo","Wierda, William","Pemmaraju, Naveen","Montalban Bravo, Guillermo","Thompson, Philip","Verstovsek, Srdan","Konopleva, Marina","Kantarjian, Hagop","Jabbour, Elias"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32392559","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1159/000508199","keywords":["acute leukemia","covid-19","chronic leukemia","myelodysplastic syndrome"],"topics":["Prevention"],"weight":1,"_version_":1666528580112220162,"score":85.154465}]}